InvestorsHub Logo
Followers 10
Posts 1265
Boards Moderated 0
Alias Born 11/10/2015

Re: Easymoneyman00 post# 37228

Thursday, 10/05/2017 8:39:08 AM

Thursday, October 05, 2017 8:39:08 AM

Post# of 108192
Even if the HER2 canine trials went very well, it makes sense for ADXS to pursue the other indications for their LM platform first, especially those in phase 3. Furthermore, HER2-positive tumors have a lot of existing and upcoming competition.

Fantastic preclinical results still puts you at least 5 or 6 years out from a product. Likely longer. It should not be read as a strong indicator that the trial went poorly.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News